PROSPECTUS SUPPLEMENT NO. 7
(TO PROSPECTUS DATED NOVEMBER 9, 2001)
ICN PHARMACEUTICALS, INC.
$525,000,000 of 6 1/2 % Convertible Subordinated Notes due 2008 and
15,326,010 Shares of Common Stock Issuable upon Conversion of the Notes
-----------------
This prospectus supplement No. 7 supplements and amends the prospectus
dated November 9, 2001, as amended by prospectus supplement No. 1 dated
December 28, 2001, prospectus supplement No. 2 dated February 26, 2002,
prospectus supplement No. 3 dated May 9, 2002, prospectus supplement No. 4
dated August 20, 2002, prospectus supplement No. 5 dated November 21, 2002,
and prospectus supplement No. 6 dated January 21, 2003, relating to the 6
1/2 % Convertible Subordinated Notes due July 15, 2008 of ICN
Pharmaceuticals, Inc., a Delaware corporation, held by certain
securityholders who may offer for sale the notes and the shares of our
common stock into which the notes are convertible at any time at market
prices prevailing at the time of sale or at privately negotiated prices.
The selling securityholders may sell the notes or the common stock directly
to purchasers or through underwriters, broker-dealers or agents, who may
receive compensation in the form of discounts, concessions or commissions.
ADDITIONAL SELLING SECURITYHOLDERS
The following represents an amendment to the table of selling
securityholders appearing on pages 46-50 of the prospectus, as supplemented
and amended:
The deletion of:
COMMON
STOCK COMMON
PRINCIPAL ISSUABLE STOCK
AMOUNT OF UPON OWNED
NOTES CONVERSION AFTER
BENEFICIALLY OF THE COMPLETION
OWNED AND NOTES AND OF THE
NAME OFFERED HEREBY OFFERED HEREBY OFFERING
---- -------------- -------------- ----------
UBS Warburg LLC $26,508,000 773,832 --
and substitution therefore of:
COMMON
STOCK COMMON
PRINCIPAL ISSUABLE STOCK
AMOUNT OF UPON OWNED
NOTES CONVERSION AFTER
BENEFICIALLY OF THE COMPLETION
OWNED AND NOTES AND OF THE
NAME OFFERED HEREBY OFFERED HEREBY OFFERING
---- -------------- -------------- ----------
UBS Warburg LLC $31,563,000 921,399 --
The prospectus, together with prospectus supplement No. 1, prospectus
supplement No. 2, prospectus supplement No. 3, prospectus supplement No. 4,
prospectus supplement No. 5, prospectus supplement No. 6 and this
prospectus supplement No. 7, constitutes the prospectus required to be
delivered by Section 5(b) of the Securities Act of 1933, as amended, with
respect to offers and sales of the notes and the common stock issuable upon
conversion of the notes. All references in the prospectus to "this
prospectus" are hereby amended to read "this prospectus (as supplemented
and amended)."
-----------------
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE
SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR
PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION
TO THE CONTRARY IS A CRIMINAL OFFENSE.
-----------------
THE DATE OF THIS PROSPECTUS SUPPLEMENT IS JUNE 13, 2003